Expert Panel Presents Positive Outcomes with TissuGlu® Surgical Adhesive at DGPRÄC Conference
28 September 2012
Bremen, Germany, September 24, 2012 - Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, recently facilitated a satellite symposium at the 43rd annual DGPRÄC conference that featured discussions with expert surgeons on their clinical experience with the use of TissuGlu Surgical Adhesive. The panel of leading surgeons presented data that described the clinical utility and cost effectiveness of TissuGlu for a wide range of large flap surgery procedures.
The symposium, titled “A New Approach to Improving Clinical Results in Flap Surgery,” presented clinical utility for the use of TissuGlu for several plastic surgery procedures. Symposium moderator Axel-Mario Feller, M.D. from Munich, who presented his center’s experience with the use of TissuGlu for DIEP flap procedures, said “TissuGlu has shown to be a clinically useful and cost effective option for reducing wound drainage and postoperative complications following a wide range of large flap plastic surgery procedures. The ability of this adhesive to permit earlier drain removal creates better clinical outcomes and improved patient satisfaction.”
Leading surgeons, who utilized TissuGlu reported the following from multiple preliminary post-market clinical series:
- Dr. Peter Stollwerck, M.D., Fachklinik Hornheide, Muenster – 50% reduction in postoperative complication rates in lymph node dissection for malignant melanoma procedures.
- Dr. Christian Eichler, M.D., Holweide Hospital, Cologne – Reduction in seroma formation following radical mastectomy procedures.
- Dr. Mathias Reutemann, M.D., Klinikum Magdeburg, Magdeburg – 50% reduction in total fluid drainage and 5 day reduction in time to drain removal in latissimus dorsi flap (LDF) procedures.
“The clinical experiences presented during this symposium reinforce the critical role of TissuGlu in helping to reduce surgical complications and improve patient comfort following a variety of large flap surgery procedures,” said Patrick Daly, President and Chief Executive Officer of Cohera Medical. “We are pleased to provide a breakthrough technology for surgeons and patients which lead to positive patient outcomes by reducing the need for post-surgical drains.”
Cohera Medical received CE Marking approval for TissuGlu and began selling product to hospitals and surgeons in Germany in September 2011. The Company plans to expand the commercial availability of TissuGlu to additional European markets in 2012. TissuGlu has been used successfully in various surgical procedures by leading surgeons.
About Cohera Medical
Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company’s first product, TissuGlu Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that help eliminate or reduce fluid accumulation and the need for post surgical drains. TissuGlu’s chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU). Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for marketing by the Food and Drug Administration (FDA) in the U.S. or in any other market. For more information, visit www.coheramed.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.